Editor’s Note: Christine Magee is an editor for CrunchBase.
Silicon Valley may have coined the ‘big data’ buzzword, but genomic scientists have been working with massive datasets for decades. Due to recent breakthroughs in DNA sequencing technology, genetics is moving from the laboratory into the market, and just about everyone is taking a keen interest.
In January, President Obama requested $215 million to fund his precision medicine initiative — $130 million to back a national research program that will track the data of 1 million volunteer donors, and another $70 million for a National Cancer Institute initiative to identify the genetic drivers of cancer.
Last week, the Bill and Melinda Gates Foundation made its largest investment yet in a $76 million equity round for CureVac, a company using mRNA as a template to make therapeutic vaccines for cancer and infectious diseases.
In 2014, genomic tech companies saw a near 50% rise in number of venture investments recorded while…
View original post 603 more words